Tregs Attenuate Peripheral Oxidative Stress and Acute Phase Proteins in ALS

Oxidative stress (OS) induces inflammation, which in turn exacerbates OS and the expression of acute phase proteins (APPs). Regulatory T lymphocyte (Treg) therapy was assessed for suppression of OS and APP responses in longitudinal serum samples from subjects with amyotrophic lateral sclerosis (ALS)...

Full description

Saved in:
Bibliographic Details
Published in:Annals of neurology Vol. 92; no. 2; pp. 195 - 200
Main Authors: Beers, David R., Thonhoff, Jason R., Faridar, Alireza, Thome, Aaron D., Zhao, Weihua, Wen, Shixiang, Appel, Stanley H.
Format: Journal Article
Language:English
Published: Hoboken, USA John Wiley & Sons, Inc 01.08.2022
Wiley Subscription Services, Inc
Subjects:
Acute phase proteins
Acute-Phase Proteins - metabolism
Amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis - metabolism
Amyotrophic Lateral Sclerosis - therapy
CD14 antigen
Clinical Trials, Phase I as Topic
Humans
Inflammation
Inflammation - metabolism
Lipopolysaccharides
Low density lipoprotein
Lymphocytes
Lymphocytes T
Oxidative Stress
Proteins
Serum levels
T-Lymphocytes, Regulatory - metabolism
Therapy
ISSN:0364-5134, 1531-8249, 1531-8249
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oxidative stress (OS) induces inflammation, which in turn exacerbates OS and the expression of acute phase proteins (APPs). Regulatory T lymphocyte (Treg) therapy was assessed for suppression of OS and APP responses in longitudinal serum samples from subjects with amyotrophic lateral sclerosis (ALS) enrolled in a phase I clinical trial. The first round of Treg therapy suppressed levels of oxidized low‐density lipoprotein (ox‐LDL). During a 6‐month washout period, ox‐LDL levels increased. A second round of therapy again suppressed ox‐LDL levels and then rose following the cessation of treatment. Serum levels of APPs, soluble CD14, lipopolysaccharide binding protein, and C‐reactive protein, were stabilized during Treg administrations, but rose during the washout period and again after therapy was discontinued. Treg therapy potentially suppresses peripheral OS and the accompanying circulating pro‐inflammatory induced APPs, both of which may serve as peripheral candidates for monitoring efficacies of immunomodulating therapies. ANN NEUROL 2022;92:195–200
Bibliography:David R. Beers and Jason R. Thonhoff are equal contributing authors.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0364-5134
1531-8249
1531-8249
DOI:10.1002/ana.26375